Use access key #2 to skip to page content.
$7.68 0.29 (3.92%)
10/13/2008 4:02 PM

Biovail Corp (USA) (BVF)

CAPS Rating:
****

A specialty pharmaceutical company that applies advanced drug-delivery technologies to improve the clinical effectiveness of medicines. Its main therapeutic areas are central nervous system disorders, pain management and cardiovascular disease.

View All Commentary (BVF)

Recs

0

Avatar MichaelTrib (< 20) Submitted: 6/02/08 6:44 PM : Outperform Start Price: $11.28 BVF Score: 3.54

Biovail has been beaten down from its 52-week high of $26.48, has a low P/E 12.01 and dishes out a nice dividend, returning 12.80 percent.





Recent buyback of 14.4 million shares is a bullish signal and an indication company officials are confident that BVF is undervalued.


Report this Post Replies: 0 | Reply

Featured Broker Partners